GT Biopharma (GTBP) EBT Margin (2010 - 2015)

GT Biopharma (GTBP) posted quarterly EBT Margin of 134300.0% for Q2 2015, up 145.82% quarter-over-quarter from 293085.71% in Q1 2015.

GT Biopharma (GTBP) EBT Margin (2010 - 2015) Analysis & Trends

GT Biopharma (GTBP) has reported EBT Margin for 5 consecutive years, with 134300.0% the latest figure, recorded in Q2 2015.

In Q2 2015, EBT Margin changed N/A year-over-year to 134300.0%; the TTM figure through Mar 2016 stood at 68695.0% (down 8720500.0% YoY), while the FY2015 annual figure was 79485.19%, up 446124.0% from the prior year.
EBT Margin grew to 134300.0% in Q2 2015 per GTBP's latest filing, from 293085.71% in the prior quarter.
Across five years, EBT Margin topped out at 134300.0% in Q2 2015 and bottomed at 293085.71% in Q1 2015.
Historically, EBT Margin has averaged 52155.19% across 4 years, with a median of 9615.0% in 2011.
Annual changes were most pronounced in 2012 — EBT Margin slumped 17460000 bps — and 2013, when it soared 6204773 bps.
GT Biopharma's EBT Margin stood at 37933.33% in 2011, then soared by 102 bps to 595.93% in 2012, then declined by 8 bps to 547.73% in 2013, then soared by 24420 bps to 134300.0% in 2015.
Business Quant data shows GTBP's EBT Margin at 134300.0% in Q2 2015, 293085.71% in Q1 2015, and 547.73% in Q1 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	139.65 Bn	131.79 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	86.08 Bn	78.09 Bn	3.93 Bn	35.61%
3	Argenx Se	65.16 Bn	59.98 Bn	1.37 Bn	35.71%
4	Moderna	63.25 Bn	58.11 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	42.22 Bn	37.12 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	31.26 Bn	27.95 Bn	992.69 Mn	13.77%
7	BioNTech SE	28.96 Bn	10.57 Bn	668.28 Mn	-25.06%
8	Insmed	27.40 Bn	26.24 Bn	358.27 Mn	-2.67%
9	Royalty Pharma	27.19 Bn	26.35 Bn	-	12.09%
10	GT Biopharma	8.68 Mn	8.68 Mn	-	-

Download Data